Premium
Melphalan Reduces the Severity of Experimental Colitis in Mice by Blocking Tumor Necrosis Factor‐α Signaling Pathway
Author(s) -
SHMARINA GALINA,
PUKHALSKY ALEXANDER,
ALIOSHKIN VLADIMIR,
SABELNIKOV ALEX
Publication year - 2007
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1397.075
Subject(s) - blocking (statistics) , tumor necrosis factor alpha , tumor necrosis factor α , melphalan , colitis , cancer research , medicine , signal transduction , necrosis , pharmacology , chemistry , multiple myeloma , computer science , biochemistry , computer network
: Melphalan is an alkylating agent, which is commonly used as an antineoplastic drug. Its cytostatic effect can be realized in humans in the dose range of 0.6–1.4 mg/kg body weight. However, previously it was shown that in the case of gradual dose decrease, the number of targets for alkylation was also reduced and the drug lost its cytostatic properties switching to cell growth modifier. It has been postulated that application of alkylating agents in such ultra‐low concentrations (50‐ to 100‐fold lower than cytostatic ones) may result in a beneficial effect in the therapy of diseases associated with mucosa inflammation. The aim of the article was to investigate the effect of ultra‐low doses of melphalan in the murine experimental colitis induced by the replacement of drinking water with 5% solution of dextran sulphate sodium (DSS). Daily administration of melphalan (25 μg/kg body weight) markedly reduced the severity of DSS‐colitis as determined by clinical and quantitative histological criteria. Both systemic and local anti‐inflammatory effects of melphalan have been observed. The possible mechanisms of the beneficial effect of the drug have been discussed.